A research team led by Case Western Reserve University’s School of Dental Medicine has received a five-year, $2.93 million grant to develop a noninvasive chairside test that could help clinicians determine whether an oral lesion needs a biopsy.
The test, called the BDI fluorescence immunoassay, measures the ratio of two naturally occurring peptides from an oral swab. The ratio corresponds with the presence of oral squamous cell carcinoma and can be read chairside in minutes.
The project pairs CWRU’s School of Dental Medicine and School of Engineering in Cleveland with Portland, Ore.-based Hemex Health, a point-of-care device company, according to an Aug. 12 news release.
The National Cancer Institute grant will support the manufacturing and clinical validation of the test. The team plans to pursue regulatory clearance in both the U.S. and India, where oral cancer rates are high but diagnostic services are limited.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place September 14-15 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
